Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ 27 Days Payable is 4,450.19 as of Dec. 2025, which is 11% above its 10-year median of 4,003.59. GuruFocus rates ASX:IIQ with a GF Score™ of 27/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Inoviq ranks better than 97.37% on this metric.
Inoviq's average Accounts Payable for the
six
months ended in Dec. 2025 was A$0.95 Mil. Inoviq's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$0.04 Mil.
Hence, Inoviq's Days Payable for the
six
months ended in Dec. 2025 was 4,450.19.
The historical rank and industry rank for Inoviq's Days Payable or its related term are showing as below:
ASX:IIQ'
s Days Payable Range Over the Past 10 Years
Min: 1466.03 Med: 4003.59 Max: 6167.67
Current: 2946.93
During the past 13 years, Inoviq's highest Days Payable was 6167.67. The lowest was 1466.03. And the median was 4003.59.
ASX:IIQ's Days Payable is ranked better than 97.37% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs ASX:IIQ: 2946.93
Inoviq's Days Payable
increased
from Dec. 2024 (4,140.78) to Dec. 2025 (4,450.19).
It may suggest that Inoviqdelayed paying its suppliers.
Inoviq Days Payable Related Terms
Inoviq Days Payable Historical Data
* Premium members only.
The historical data trend for Inoviq's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IIQ vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Inoviq's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Days Payable distribution charts can be found below:
* The bar in red indicates where Inoviq's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Inoviq's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (ASX:IIQ) has a Days Payable of 4,450.19 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inoviq and its competitors. This is 11% above median its historical median of 4,003.59. Over the past decade, Inoviq's Days Payable has ranged from 1,466.03 to 6,167.67. According to the industry distribution chart, Inoviq ranks #5 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 2.6%.
Is Inoviq's Days Payable too high?
Inoviq's current Days Payable of 4,450.19 is 11% above median its 10-year median of 4,003.59. Over the past 10 years, this metric has ranged from a low of 1,466.03 to a high of 6,167.67. The Medical Diagnostics & Research industry median Days Payable is 64.64. Inoviq's value of 4,450.19 is 6784.6% above this industry median. Based on the distribution chart, Inoviq ranks #5 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Inoviq has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #5 out of 190 companies for Days Payable. This places Inoviq in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.64. Inoviq's value of 4,450.19 is 6784.6% above this benchmark. Historically, Inoviq's own Days Payable has ranged from 1,466.03 to 6,167.67 over the past decade. While the company's 10-year median is 4,003.59 vs. the industry median of 64.64, Inoviq has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inoviq's current Days Payable of 4,450.19 is 6784.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inoviq and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current Days Payable is 4,450.19, which is 11% above median its own 10-year median of 4,003.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.20 — trading 60.8% below its estimated fair value. The current Days Payable is 4,450.19, which is 11% above median its 10-year median of 4,003.59 and 6784.6% above the Medical Diagnostics & Research industry median of 64.64. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current Days Payable is 4,450.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
Days Payable: 4,450.19 (11% above median its 10-year median of 4,003.59)
GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
Industry Position: 6784.6% above the Medical Diagnostics & Research median (#5 of 190)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for ASX:IIQ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
